keyword
MENU ▼
Read by QxMD icon Read
search

trospium solifenacin

keyword
https://www.readbyqxmd.com/read/29723926/variation-in-cardiovascular-risk-related-to-individual-antimuscarinic-drugs-used-to-treat-overactive-bladder-a-cohort-study-in-the-uk
#1
Alejandro Arana, Andrea V Margulis, Lisa J McQuay, Ryan Ziemiecki, Jennifer L Bartsch, Kenneth J Rothman, Billy Franks, Milbhor D Silva, Kwame Appenteng, Cristina Varas-Lorenzo, Susana Perez-Gutthann
BACKGROUND: Blocking muscarinic receptors could have an effect upon cardiac function, especially among elderly patients with overactive bladder (OAB). STUDY OBJECTIVE: To investigate the risk of cardiovascular events in users of antimuscarinic drugs to treat OAB. DESIGN, SETTING AND PARTICIPANTS: Cohort study of new users of darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine, or trospium, aged ≥18 years old in the United Kingdom's Clinical Practice Research Datalink (CPRD), 2004-2012...
May 3, 2018: Pharmacotherapy
https://www.readbyqxmd.com/read/29709423/basic-and-clinical-aspects-of-antimuscarinic-agents-used-to-treat-overactive-bladder
#2
REVIEW
Shizuo Yamada, Yoshihiko Ito, Saori Nishijima, Katsumi Kadekawa, Kimio Sugaya
Antimuscarinic agents are now widely used as the pharmacological therapy for overactive bladder (OAB) because neuronal (parasympathetic nerve) and non-neuronal acetylcholine play a significant role for the bladder function. In this review, we will highlight basic and clinical aspects of eight antimuscarinic agents (oxybutynin, propiverine, tolterodine, solifenacin, darifenacin, trospium, imidafenacin, and fesoterodine) clinically used to treat urinary dysfunction in patients with OAB. The basic pharmacological characteristics of these eight antimuscarinic agents include muscarinic receptor subtype selectivity, functional bladder selectivity, and muscarinic receptor binding in the bladder and other tissues...
April 27, 2018: Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29686801/cost-effectiveness-of-solifenacin-compared-with-oral-antimuscarinic-agents-for-the-treatment-of-patients-with-overactive-bladder-in-the-uk
#3
Zalmai Hakimi, Con Kelleher, Samuel Aballéa, Khaled Maman, Jameel Nazir, Colette Mankowski, Isaac Odeyemi
Objective: To evaluate the cost-effectiveness of solifenacin 5 mg/day versus other oral antimuscarinic agents used for overactive bladder (OAB) from a UK National Health Service (NHS) perspective. Study design: In a Markov model, hypothetical patients received solifenacin 5 mg/day or a comparator antimuscarinic, after which they could switch to an alternative antimuscarinic. The model estimated incremental cost-effectiveness ratios (ICER), expressed as cost per quality-adjusted life year (QALY) over a 5-year period...
2018: Journal of Market Access & Health Policy
https://www.readbyqxmd.com/read/29609422/influence-of-the-short-term-intake-of-high-doses-of-solifenacin-and-trospium-on-cognitive-function-and-health-related-quality-of-life-in-older-women-with-urinary-incontinence
#4
Kirill Kosilov, Irina Kuzina, Sergay Loparev, Yuliya Gainullina, Liliya Kosilova, Alexandra Prokofyeva
PURPOSE: The aim of this study was to investigate the safety and the effects of elevated doses of solifenacin and trospium on cognitive function and health-related quality of life (HRQoL) in elderly women receiving treatment for urinary incontinence. METHODS: The study included 312 women aged 60-83 years (mean age, 69.4 years). All participants had scored at least 24 points on the Mini-Mental State Examination (MMSE) scale, and all of them had been diagnosed with urge urinary incontinence (UUI) or mixed urinary incontinence (MUI)...
March 2018: International Neurourology Journal
https://www.readbyqxmd.com/read/29496263/evaluating-the-effect-of-three-newly-approved-overactive-bladder-syndrome-treating-agents-on-parotid-and-submandibular-salivary-glands-modulation-of-cxcl10-expression
#5
Basma Emad Aboulhoda, Eid Nassar Ali
BACKGROUND: Despite enormous progresses in understanding pathophysiology of the lower urinary tract, antimuscarinics remain the chief clinically well-established approach for improving symptoms of overactive bladder (OAB). Dry mouth on the other hand remains one of the most untolerated systemic side effects of these drugs that limits their uses and results in high discontinuation rate. Three novel drugs have been recently approved by US Food and Drug Administration for treatment of OAB: trospium, darifenacin, and solifenacin...
April 2018: Acta Histochemica
https://www.readbyqxmd.com/read/29492862/differential-prescribing-of-antimuscarinic-agents-in-older-adults-with-cognitive-impairment
#6
Scott Martin Vouri, Mario Schootman, Seth A Strope, Stanley J Birge, Margaret A Olsen
BACKGROUND: Oral oxybutynin has been associated with the development of cognitive impairment. OBJECTIVE: The objective of this study was to describe the use of oral oxybutynin versus other antimuscarinics (e.g., tolterodine, darifenacin, solifenacin, trospium, fesoterodine, transdermal oxybutynin) in older adults with documented cognitive impairment. METHODS: This is a population-based retrospective analysis of antimuscarinic new users aged ≥ 66 years from January 2008 to December 2011 (n = 42,886) using a 5% random sample of Medicare claims linked with Part D data...
April 2018: Drugs & Aging
https://www.readbyqxmd.com/read/29345103/incidence-of-common-cancers-in-users-of-antimuscarinic-medications-for-overactive-bladder-a-danish-nationwide-cohort-study
#7
Jesper Hallas, Andrea V Margulis, Anton Pottegård, Nina Sahlertz Kristiansen, Willem Jan Atsma, Kwame Appenteng, Stefan de Vogel, James A Kaye, Susana Perez-Gutthann, Alejandro Arana
The purpose of this study was to estimate the incidence rate (IR) of 10 common cancers in new users of antimuscarinic overactive bladder (OAB) medications. We conducted a cohort study using data recorded in Danish registers for patients newly exposed to the OAB drugs darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine or trospium in years 2004-2012, aged ≥18 years and without cancer before treatment initiation. We estimated IRs for each study cancer (bladder, breast, colorectal, lung, melanoma, non-Hodgkin lymphoma, pancreas, prostate, renal and uterine), standardised by age and sex and explored IR trends over time since treatment initiation...
January 17, 2018: Basic & Clinical Pharmacology & Toxicology
https://www.readbyqxmd.com/read/29134254/comparison-of-cardiovascular-events-among-treatments-for-overactive-bladder-a-danish-nationwide-cohort-study
#8
Andrea V Margulis, Jesper Hallas, Anton Pottegård, Nina Sahlertz Kristiansen, Willem Jan Atsma, Billy Franks, Milbhor D'Silva, Cristina Varas-Lorenzo, Susana Perez-Gutthann, Alejandro Arana
PURPOSE: The purpose of this study is to explore the cardiovascular safety of antimuscarinic drugs to treat overactive bladder (OAB) in Denmark. METHODS: This was a cohort study using data recorded in Danish registries from patients newly exposed to darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine, or trospium in 2004-2012. We estimated crude and standardized incidence rates (IRs) for acute myocardial infarction (AMI); stroke; cardiovascular mortality; major adverse cardiac events (MACE, a combined endpoint of the previous three outcomes); and all-cause death for the individual and combined drugs...
February 2018: European Journal of Clinical Pharmacology
https://www.readbyqxmd.com/read/28747995/assessment-of-inhibitory-effects-on-major-human-cytochrome-p450-enzymes-by-spasmolytics-used-in-the-treatment-of-overactive-bladder-syndrome
#9
Dominik Dahlinger, Sevinc Aslan, Markus Pietsch, Sebastian Frechen, Uwe Fuhr
BACKGROUND: The objective of this study was to examine the inhibitory potential of darifenacin, fesoterodine, oxybutynin, propiverine, solifenacin, tolterodine and trospium chloride on the seven major human cytochrome P450 enzymes (CYP) by using a standardized and validated seven-in-one cytochrome P450 cocktail inhibition assay. METHODS: An in vitro cocktail of seven highly selective probe substrates was incubated with human liver microsomes and varying concentrations of the seven test compounds...
July 2017: Therapeutic Advances in Urology
https://www.readbyqxmd.com/read/28505926/re-effectiveness-of-solifenacin-and-trospium-for-managing-of-severe-symptoms-of-overactive-bladder-in-patients-with-benign-prostatic-hyperplasia
#10
https://www.readbyqxmd.com/read/28370075/cancer-incidence-after-initiation-of-antimuscarinic-medications-for-overactive-bladder-in-the-united-kingdom-evidence-for-protopathic-bias
#11
James A Kaye, Andrea V Margulis, Joan Fortuny, Lisa J McQuay, Estel Plana, Jennifer L Bartsch, Christine L Bui, Susana Perez-Gutthann, Alejandro Arana
STUDY OBJECTIVE: To estimate the incidence of 10 common cancers among patients treated with antimuscarinic medications for overactive bladder (AMOABs). DESIGN: Retrospective cohort study. DATA SOURCE: United Kingdom's Clinical Practice Research Datalink. PATIENTS: A total of 119,912 adults with no previous cancer diagnosis who were new users of AMOABs-darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine, or trospium-between January 2004 and December 2012...
June 2017: Pharmacotherapy
https://www.readbyqxmd.com/read/28265325/overactive-bladder-in-children
#12
REVIEW
Sophie Ramsay, Stéphane Bolduc
Overactive bladder (OAB) is a highly prevalent disorder in the pediatric population. This condition is especially troublesome for pediatric patients and their families when associated with incontinence, since it negatively affects self-esteem and impairs children's development. From the patient's perspective, urgency and urge incontinence can have a significant impact, negatively affecting their quality of life. For a therapy to have true benefit, changes must not only be statistically significant, but must also be perceived as meaningful by the patient...
January 2017: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/28196724/persistence-and-adherence-with-mirabegron-versus-antimuscarinic-agents-in-patients-with-overactive-bladder-a-retrospective-observational-study-in-uk-clinical-practice
#13
Christopher R Chapple, Jameel Nazir, Zalmai Hakimi, Sally Bowditch, Francis Fatoye, Florent Guelfucci, Amine Khemiri, Emad Siddiqui, Adrian Wagg
BACKGROUND: Persistence with antimuscarinic therapy in overactive bladder (OAB) is poor, but may be different for mirabegron, a β3-adrenoceptor agonist with a different adverse event profile. OBJECTIVE: To compare persistence and adherence with mirabegron versus tolterodine extended release (ER) and other antimuscarinics in routine clinical practice over a 12-mo period. DESIGN, SETTING, AND PARTICIPANTS: Retrospective, longitudinal, observational study of anonymised data from the UK Clinical Practice Research Datalink GOLD database...
September 2017: European Urology
https://www.readbyqxmd.com/read/28091711/anticholinergic-prescription-are-healthcare-professionals-the-real-burden
#14
George Araklitis, Ganesh Thiagamoorthy, Jo Hunter, Angie Rantell, Dudley Robinson, Linda Cardozo
INTRODUCTION AND HYPOTHESIS: Anticholinergic medication is the medical treatment for overactive bladder (OAB). These drugs can act on the central nervous system and can lead to cognitive decline, dementia, and potentially death. Patients taking drugs with anticholinergic effects increase their anticholinergic burden-defined as the cumulative effect of taking one or more drugs that can have adverse effects. When prescribing anticholinergic medication for the elderly, we must choose the right drug...
August 2017: International Urogynecology Journal
https://www.readbyqxmd.com/read/28074677/the-effective-tool-for-self-assessment-of-adherence-to-treatment-in-patients-with-benign-prostatic-obstruction-and-overactive-bladder-symptoms
#15
RANDOMIZED CONTROLLED TRIAL
Kirill Kosilov, Sergey Loparev, Irina Kuzina, Olga Shakirova, Natalya Zhuravskaya, Alexandra Lobodenko
PURPOSE: Study of validity of the Medication Adherence Self-Report Inventory (MASRI) for use in clinical practice to treat patients with benign prostatic obstruction (BPO) accompanied with overactive bladder (OAB) symptoms. METHODS: During 12 weeks of the randomized study, 452 patients with BPO and OAB symptoms (mean age of 61.3 (12.7)) were studied for adherence to the treatment with Tamsulosin, Solifenacin and Trospium using the MASRI. External monitoring instruments included the Brief Medication Questionnaire (BMQ) and the visual remaining pill count...
March 2017: Aging Male: the Official Journal of the International Society for the Study of the Aging Male
https://www.readbyqxmd.com/read/28050642/randomized-double-blind-placebo-controlled-trial-to-compare-solifenacin-versus-trospium-chloride-in-the-relief-of-double-j-stent-related-symptoms
#16
Mohamed H Abdelhamid, Ahmed S Zayed, Waleed E Ghoneima, Akrm A Elmarakbi, Mohamed S El Sheemy, Ahmed Aref, Ahmed Abdelbary, Hani H Nour
PURPOSE: We aimed to compare the safety and efficacy of solifenacin versus trospium chloride and compare each drug versus placebo regarding the relief of stent-related symptoms following uncomplicated ureteroscopic lithotripsy (URSL). METHODS: In a prospective, randomized, double-blind study, 210 eligible patients who underwent URSL with double-J stent insertion were recruited and randomly assigned to either the first group, receiving solifenacin (10 mg), second group, receiving trospium chloride (60 mg), or the third group, receiving placebo (one tablet)...
August 2017: World Journal of Urology
https://www.readbyqxmd.com/read/28025920/impact-of-overactive-bladder-step-therapy-policies-on-medication-utilization-and-expenditures-among-treated-medicare-members
#17
Ibrahim M Abbass, Eleanor O Caplan, Daniel B Ng, Rita Kristy, Carol R Schermer, Pamela Bradt, Jenna M Collins, Wai Man Maria Chan, Brandon T Suehs
BACKGROUND: The impact of formulary management strategies on utilization and expenditures in overactive bladder (OAB) treatment has not been extensively investigated. In 2013, step therapy (ST) policies for 2 branded OAB treatments, mirabegron and fesoterodine, were removed from Humana Medicare Advantage Prescription Drug (MAPD) plans and Medicare prescription drug plans (PDP), allowing for an examination of the effect of ST policies on OAB medication use patterns and costs. OBJECTIVE: To assess the impact of removal of formulary restriction policies for mirabegron and fesoterodine on medication utilization patterns and costs associated with OAB treatment in Medicare patients...
January 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/27988174/-medico-economic-evaluation-of-urological-cares-of-spinal-cord-injured-patients-a-review
#18
REVIEW
C Guillot-Tantay, E Chartier-Kastler, Q Manach, M-A Perrouin-Verbe, P Denys, V Phé
INTRODUCTION: To provide an overview of the urological management of spinal cord injured patients based on an economic analysis. MATERIALS AND METHODS: A literature search from January 1994 to December 2014 was performed using Medline and Embase database using the following keywords: cost-effectiveness; cost-benefit; cost-utility; spinal cord injury; neurogenic bladder; intermittent catheterization; antimuscarinics; botulinum toxin; sacral neuromodulation; tibial nerve; Brindley; sphincterotomy...
January 2017: Progrès en Urologie
https://www.readbyqxmd.com/read/27935011/electrical-stimulation-with-non-implanted-electrodes-for-overactive-bladder-in-adults
#19
REVIEW
Fiona Stewart, Luis F Gameiro, Regina El Dib, Monica O Gameiro, Anil Kapoor, Joao L Amaro
BACKGROUND: Several options exist for managing overactive bladder (OAB), including electrical stimulation (ES) with non-implanted devices, conservative treatment and drugs. Electrical stimulation with non-implanted devices aims to inhibit contractions of the detrusor muscle, potentially reducing urinary frequency and urgency. OBJECTIVES: To assess the effects of ES with non-implanted electrodes for OAB, with or without urgency urinary incontinence, compared with: placebo or any other active treatment; ES added to another intervention compared with the other intervention alone; different methods of ES compared with each other...
December 9, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27928426/treatment-compliance-of-working-persons-to-high-dose-antimuscarinic-therapies-a-randomized-trial
#20
Kirill Vladimirovich Kosilov, Sergey Loparev, Irina Kuzina, Olga Shakirova, Nataliya Zhuravskaya, Alexandra Lobodenko
AIM: The aim of this work was to study the factors affecting the stability of working patients in antimuscarinic (AM) drug treatment. BACKGROUND: The prevalence of urge urinary incontinence (UUI) is an average of between 8.2% and 16.0% of the population. UUI is a condition that adversely affects the health-related quality of life. The first-line therapy in managing UUI is AM treatment. METHODS: In 1006 patients between 18 and 60 years old (627 women, 379 men, mean age 69...
August 2016: Therapeutic Advances in Urology
keyword
keyword
102019
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"